Trial Profile
A double-blind, randomized, comparative study of Cabaser [cabergoline] and Sinemet CR [controlled-release levodopa/carbidopa] for the treatment of nocturnal disability in levodopa-treated Parkinson's disease patients
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2005
Price :
$35
*
At a glance
- Drugs Cabergoline (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Dec 2005 New trial record.